CN-121991840-A - Streptococcus agalactiae, application thereof and microbial agent

Abstract

The present invention relates to the field of microbiological technology and discloses a non lactose solubilizing streptococcus and its application and microbial agent. The non lactose solubilizing streptococcus strain is named streptococcus alactolyticus 0625. The strain was deposited on December 1, 2025 at the General Microbiology Center of the China Microbial Culture Collection Management Committee, with the deposit number CGMCC No. 36838. The non lactose solubilizing streptococcus alactolyticus 0625 provided by the present invention has been verified to effectively improve intestinal inflammation, laying a solid foundation for the development of related microbial therapy products.

Inventors

• WU SHUSONG
• LI JISEN
• Yin Zhangzheng

Assignees

• 湖南农业大学

Dates

Publication Date

20260508

Application Date

20260129

Claims (7)

1. 1. A streptococcus agalactiae (streptococcus alactolyticus) strain, characterized in that the streptococcus agalactiae (streptococcus alactolyticus) strain is named streptococcus alactolyticus0625, and is preserved in China general microbiological culture collection center (CGMCC) with a preservation number of 36838 in the year 2025, month 12 and 01.
2. 2. The non-lactose degrading streptococcus strain according to claim 1, wherein the non-lactose degrading streptococcus (streptococcus alactolyticus) strain is isolated from C57BL/6 mouse faeces.
3. 3. A microbial agent comprising the streptococcus not-lactose-degrading (streptococcus alactolyticus) strain of claim 1 or 2 and a pharmaceutically or feedstuffs acceptable carrier.
4. 4. The microbial agent of claim 3, wherein the viable count of the non-lactose-degrading streptococcus (streptococcus alactolyticus) strain in the microbial agent is 1 x 10 8 CFU/mL to 1 x 10 10 CFU/mL.
5. 5. Use of a strain of streptococcus agalactiae (streptococcus alactolyticus) according to claim 1 or 2 or of a microbial agent according to claim 3 for the preparation of a composition for the prevention and/or treatment of intestinal inflammation.
6. 6. The use according to claim 5, wherein the intestinal inflammation is an intestinal inflammation induced by dextran sodium sulfate.
7. 7. A food, nutraceutical or feed additive comprising the streptococcus agalactiae (streptococcus alactolyticus) strain of claim 1 or 2 or the microbial agent of claim 3.

Description

Streptococcus agalactiae, application thereof and microbial agent Technical Field The invention relates to the technical field of microorganisms, in particular to non-lactose-decomposing streptococcus and application thereof, and a microbial agent. Background Intestinal health is a key to maintaining the overall physiological balance of the body, and the incidence of inflammatory diseases of the intestinal tract, such as Inflammatory Bowel Disease (IBD), is on a continuous rise worldwide. The disease is prolonged in course and easy to repeatedly attack, and seriously affects the life quality of patients. The current clinical treatment strategies mainly depend on anti-inflammatory drugs, immunosuppressants and even biological agents, and the means can control symptoms to a certain extent, but the problems of strong side effects, high treatment cost and the like caused by long-term use are generally existed. Therefore, the development of alternative or adjuvant therapeutic regimens that are safe, effective, and novel in mechanism of action would be of great clinical need and practical significance. With the intensive microbiological research, the intestinal flora is increasingly gaining importance as a "forgotten organ" of the human body. The use of probiotics to regulate intestinal microecological balance has proven to be a potentially effective way to intervene in intestinal inflammation. However, probiotic products currently on the market and in scientific research have been concentrated on a few traditional genera of lactobacillus, bifidobacterium, etc. The general strain has obvious limitations that firstly, the strain specificity is strong, the efficacy difference of different strains is huge, the cost for screening strains with stable and obvious anti-inflammatory activity is high, the period is long, secondly, a plurality of external probiotics are difficult to colonize and have low survival rate in a complex internal environment of a host, especially in an inflammatory state, so that the actual efficacy is greatly reduced, and furthermore, the explanation of the anti-inflammatory mechanism of the probiotics in the prior study is still not deep enough and the system is limited, so that the accurate application of the probiotics is limited. In this context, isolation of the native strain from within the intestinal tract of a healthy host is a more promising technological route. The original strains have natural adaptability to intestinal environments in a long co-evolution process, and are easier to colonize and function in vivo. However, how to efficiently screen out specific strains with excellent intestinal adaptability and clear and strong anti-inflammatory function from a large number of intestinal microorganisms, and verify the efficacy thereof by using a reliable in vivo model is a major technical bottleneck faced by those skilled in the art. Therefore, a novel microbial resource which has clear sources, definite functions and can effectively improve intestinal inflammation through strict scientific verification is urgently needed in the field so as to fill the defects of the existing probiotics in the aspects of specificity, effectiveness and mechanism definition. Disclosure of Invention The invention aims to provide a microbial resource capable of improving intestinal inflammation so as to fill the defects of the existing probiotics in the aspects of specificity, effectiveness and mechanism definition. In order to achieve the above object, a first aspect of the present invention provides a non-lactose-decomposing streptococcus (streptococcus alactolyticus) strain, the non-lactose-decomposing streptococcus (streptococcus alactolyticus) strain is streptococcus alactolyticus0625, and the strain is preserved in China general microbiological culture Collection center (CGMCC) with a preservation number of 36838 in 12-month 01 of 2025. In a second aspect, the invention provides a microbial agent comprising the non-lactose degrading streptococcus strain of the first aspect and a pharmaceutically or feedstuffs acceptable carrier. In a third aspect, the invention provides the use of a streptococcus agalactiae (streptococcus alactolyticus) strain according to the first aspect or a microbial agent according to the second aspect in the manufacture of a composition for the prevention and/or treatment of intestinal inflammation. In a fourth aspect, the invention provides a food, health product or feed additive comprising a streptococcus agalactiae (streptococcus alactolyticus) strain according to the first aspect or a microbial agent according to the second aspect. Compared with the prior art, the invention has at least the following beneficial effects: (1) The non-lactose-dissolving streptococcus provided by the invention has definite functions and obvious curative effect. This particular strain of non-lactose-degrading streptococcus isolated from the intestinal tract of healthy mammals was found and valida